Tisotumab vedotin plus carboplatin or pembrolizumab in recurrent or metastatic cervical cancer: 5-year results from the innovaTV 205/ENGOT-cx8/GOG-3024 study.
Van Nieuwenhuysen E, Vergote I, Randall LM, Tromp J, Lorusso D, O'Cearbhaill RE, Boere I, Pisano C, Sanchez LM, Banerjee S, Collins DC, Zikán M, Mathews C, Kümmel J, Melichar B, Jackson AL, Madsen K, Gennigens C, Ottevanger N, Ghamande S, Salutari V, Baurain JF, Reyners AKL, Chisamore M, Conte U, Windfeld K, Geiger M, Hansen H, Denys H, Cibula D, Oaknin A, Van Gorp T, Monk BJ; innovaTV 205/ENGOT-cx8/GOG-3024 investigators.
Van Nieuwenhuysen E, et al.
Gynecol Oncol. 2026 Apr;207S:3-13. doi: 10.1016/j.ygyno.2026.02.008.
Gynecol Oncol. 2026.
PMID: 42000372
Free article.
Clinical Trial.
METHODS: innovaTV 205/ENGOT-cx8/GOG-3024 (NCT03786081) was a multicenter, open-label phase 1b/2 study, which included dose-expansion arms of 1L TV + carboplatin (arm D), 1L/2L+ TV + pembrolizumab (arms E/F), and 1L TV + carboplatin + pembrolizumab bevacizum …
METHODS: innovaTV 205/ENGOT-cx8/GOG-3024 (NCT03786081) was a multicenter, open-label phase 1b/2 study, which included dose-expansion arms …